390 likes | 408 Vues
This conference explores rising breast cancer cases in young women, aggressive treatment options, endocrine therapy, and ovarian function suppression. Discussions include radical mastectomy, fertility preservation, and chemotherapy-induced amenorrhea.
E N D
Management of Breast cancer in young Women D.Amer Al shikhyosef Director of Kiwan cancer care centre General secretary of S.I.A.C Breast cancer in young women Challenges and hopes Dr Amer chikhyoussef
(In Asia new cases are rising substantially by around 60% in some parts over the space of 10 years the rise is particularly in younger women between 30and 40) Dr.Louis Chow medical director of comprehensive centre of breast disease Hong Kong 1st Asian breast cancer conference Delhi India 2008
breast cancer incidence per 100,000 in Iran2005-2006 Montazari et al. IHSR
Should treatment options for young women be more aggressive?
Age that may considered as risk factor ? Risk of long term sequel of aggressive treatment ( CHF - leukemia)
Although there is no biologic explanationFor the increase of risk for recurrancr one should carefully considre more rather less treatment and we also need to discus emerging stratigy .
Endocrine therapy What is the role of suppression of ovarian function? Optimal duration of endocrine therapy in young women?
Conclusion : • Ovarian suppression in some selected high risk patients. • Careful assessment of QL.
Optimal duration of hormonal therapy for young patients? ATLAS study: 10 vs.5 years of tamoxifen
Conclusion : • The standard duration 5y • in high risk N+ AIs after 5 y tamoxifen should be considered (permanent amenorrhea du to chemotherapy)